Publish in this journal
Journal Information
Vol. 68. Issue 11.
Pages 1040-1041 (November 2015)
Letter to the Editor
DOI: 10.1016/j.rec.2015.07.005
Full text access
Beta-blocker Use After an Acute Coronary Syndrome. Which one, in Whom, and for How Long?
Tras un síndrome coronario agudo, ¿qué bloqueador beta se debería dar, a quién y cuánto tiempo?
Alberto Cordero
Corresponding author

Corresponding author:
, Pilar Carrillo, Ramón López-Palop
Departamento de Cardiología, Hospital Universitario de San Juan, San Juan de Alicante, Alicante, Spain
Related content
Rev Esp Cardiol. 2015;68:585-9110.1016/j.rec.2014.07.028
Sergio Raposeiras-Roubín, Emad Abu-Assi, Alfredo Redondo-Diéguez, Rocío González-Ferreiro, Andrea López-López, Noelia Bouzas-Cruz, María Castiñeira-Busto, Carlos Peña Gil, José María García-Acuña, José Ramón González-Juanatey
Rev Esp Cardiol. 2015;68:104110.1016/j.rec.2015.07.017
Sergio Raposeiras Roubín, Emad Abu-Assi, José Ramón González-Juanatey
This item has received
(Daily data update)
Article information
Full Text
Download PDF
Full Text
To the Editor,

Having read the article by Raposeiras-Roubín et al,1 we feel that it warrants a number of considerations, since beta-blockers (BB) are the only drugs used in optimal medical therapy following acute coronary syndrome (ACS) that are currently being questioned. In their analysis of the long-term effect of BB therapy on ACS patients with an ejection fraction > 50% at discharge, a subgroup of patients without a clear indication for this treatment, the authors found a 36% reduction in 5-year mortality.

At present, 3 points are considered to be central to BB therapy following ACS. Firstly, although the use of BB has increased exponentially over the past decade,2,3 a recent meta-analysis shows that, in the reperfusion era, no benefit is observed with BB therapy after ACS.4 Secondly, the guidelines for secondary prevention issued by the American Heart Association and the American College of Cardiology5 recommend the use of only those BB—carvedilol, metoprolol, and bisoprolol—that have been shown to improve survival after ACS; moreover, they recommend a treatment duration of at least 3 years, and acknowledge that it seems logical to prolong their use indefinitely, although there is no available evidence in this regard. Thirdly, as these agents do not appear to provide any benefit in terms of prognosis or recurrence of major cardiovascular complications in patients with stable chronic ischemic heart disease,6 the appropriate duration of the treatment is unknown.

In the DIOCLES registry,3 81% of the patients received BB at discharge, more than 20% more than in the MASCARA registry (67.8%).7 During the interval between these 2 registries, there was also an increase in the frequency of revascularization, from 63%6 to 85%.2 However, in the study by Rasposeiras-Roubín et al,1 the rate of interventional procedures did not exceed 70%, possibly because it includes patients admitted as long ago as 2003, corresponding to a period prior to the MASCARA registry.7 On the other hand, none of the publications mention which BB were administered. For the first time, the 2011 guidelines for secondary prevention of the American Heart Association and the American College of Cardiology included the recommendation that only those agents that have been found to improve survival be administered, given that some of them have not been studied in the post-ACS context or have not even been shown to have any beneficial effect, as is the case of atenolol.5 A Spanish registry of patients with chronic ischemic heart disease revealed that precisely those drugs recommended by the American Heart Association and the American College of Cardiology are associated with good resting heart rate control,8 a finding that has been directly correlated with an improved prognosis.

Thus, we consider that the article provides solid and clinically relevant evidence regarding the use of BB in patients with ACS, although, in our setting, there continues to be an important lack of knowledge as to which BB should be administered to which patients and for how long after ACS.

S. Raposeiras-Roubín, E. Abu-Assi, A. Redondo-Diéguez, R. González-Ferreiro, A. López-López, N. Bouzas-Cruz, et al.
¿En la era actual existe beneficio pronóstico del tratamiento con bloqueadores beta tras un síndrome coronario agudo con función sistólica conservada?.
Rev Esp Cardiol., 68 (2015), pp. 585-591
K.L. Park, R.J. Goldberg, F.A. Anderson, J. López-Sendón, G. Montalescot, D. Brieger, et al.
Beta-blocker use in ST-segment elevation myocardial infarction in the reperfusion era (GRACE).
Am J Med., 127 (2014), pp. 503-511
J.A. Barrabés, A. Bardají, J. Jiménez-Candil, F. del Nogal Sáez, V. Bodí, N. Basterra, et al.
Pronóstico y manejo del síndrome coronario agudo en España en 2012: estudio DIOCLES.
Rev Esp Cardiol., 68 (2015), pp. 98-106
S. Bangalore, H. Makani, M. Radford, K. Thakur, B. Toklu, S.D. Katz, et al.
Clinical outcomes with beta-blockers for myocardial infarction: a meta-analysis of randomized trials.
Am J Med., 127 (2014), pp. 939-953
S.C. Smith Jr., E.J. Benjamin, R.O. Bonow, L.T. Braun, M.A. Creager, B.A. Franklin, et al.
AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation.
Circulation., 124 (2011), pp. 2458-2473
S. Bangalore, G. Steg, P. Deedwania, K. Crowley, K.A. Eagle, S. Goto, et al.
ß-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease.
JAMA., 308 (2012), pp. 1340-1349
I. Ferreira-González, G. Permanyer-Miralda, J. Marrugat, M. Heras, J. Cuñat, E. Civeira, et al.
Estudio MASCARA (Manejo del Síndrome Coronario Agudo. Registro Actualizado). Resultados globales.
Rev Esp Cardiol., 61 (2008), pp. 803-816
A. Cordero, V. Bertomeu-González, P. Mazón, J. Moreno-Arribas, L. Fácila, H. Bueno, et al.
Differential effect of ß-blockers for heart rate control in coronary artery disease.
Clin Cardiol., 34 (2011), pp. 748-754
Copyright © 2015. Sociedad Española de Cardiología
Revista Española de Cardiología (English Edition)

Subscribe to our newsletter

Article options
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

es en
Política de cookies Cookies policy
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here.